Multicenter, double-blind, parallel-group, randomised, 48 weeks, dose-ranging, placebo-controlled phase II trial to evaluate efficacy, safety and tolerability of multiple subcutaneous (s.c.) doses of BI456906 in patients with non-alcoholic steatohepatitis (NASH) and Fibrosis

  • Pianko, Stephen (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusActive
Effective start/end date2/12/21 → 1/12/26

Keywords

  • multicentre trial
  • treatment safety
  • treatment efficacy
  • steatohepatitis

Clinical Trial Phase

  • Phase II